REAL-LIFE DATA OF PAZOPANIB USAGE IN SOFT TISSUE SARCOMA

Öz

Abstract: Objective: Soft tissue sarcomas are heterogeneous group of malignancies consisting of more than 50 subtypes. Although it is rare, it is usually resistant to chemotherapy and has a poor prognosis. In this study, we planned to investigate the efficacy, tolerability and side-effect profile of pazopanib in metastatic soft tissue sarcomas. Method-Material: Our study was a single-center retrospective study and included metastatic patients over the age of 18 who were treated with pazopanib. Data of 37 patients were obtained in retrospective medical records. In patients using pazopanib; Tumor location, histological subtype, tumor grade, disease stage, the line at which pazopanib was used, efficacy, tolerability, and side-effect profile of pazopanib were examined. Findings: The mean age of the patients at diagnosis was 49. Pleomorphic sarcoma was the most common subtype. The progression-free survival (PFS) of patients after first-line therapy was 18 weeks. The median overall survival (OS) of the patients was 20 months. The median PFS with pazopanip was 18 weeks. Conclusion: In the study we conducted research in terms of effectiveness and side effects; the use of pazopanib in soft tissue sarcoma was found to be effective in terms of both PFS and OS. Side effects were tolerable and treatable. In our study, a PFS of 32 weeks was obtained in patients with hypothyroidism and at 16 weeks in patients who did not. In this respect, development of hypothyroidism may be a predictive parameter for response.

Anahtar Kelimeler

• pazopanib
• hypothyroidism
• side effect
• sarcoma

YUMUŞAK DOKU SARKOMUNDA PAZOPANIB KULLANIMINA İLİŞKİN GERÇEK HAYAT VERİLERİ

Öz

Özet Amaç: Yumuşak doku sarkomu 50 den fazla alt sınıftan oluşan heterojen bir malignite grubudur. Nadir görülmekle birlikte genellikle kemoterapiye dirençli olup, prognozu kötüdür. Çalışmamızda metastatik yumuşak doku sarkomlarında pazopanib kullanımının etkinliği, tolerabilitesi ve yan etki profilini araştırmayı planladık. Yöntem: Çalışmamız tek merkezli retrospektif bir çalışma olup, metastatik olan ve pazopanib alan 18 yaş üstü hastalar dahil edildi. Geriye yönelik dosya taramasında toplam 37 hastanın verisine ulaşıldı. Pazopanib kullanan hastalarda; tümörün yerleşim yeri, histolojik alt tipi, tümör derecesi, hastalığın evresi, pazopanibin hangi basamakta başlandığı, pazopanibin etkinliği, tolerabilitesi, ve yan etki profili incelendi. Bulgular: Hastaların tanı sırasında ortalama yaş 49. Pleomorfik sarkom en sık görülen alt tip idi. Birinci basamak tedavi sonrası hastaların progresyonsuz sağ kalımı (PFS) 18 hafta idi. Hastaların genel sağ kalım (OS) ortanca sağ kalım 20 ay bulundu. Pazopanib ile ortanca PFS 18 hafta olarak saptandı. Sonuç: Etkinlik ve yan etki yönünden araştırma yaptığımız çalışmada; yumuşak doku sarkomunda pazopanib kullanımı hem PFS hem OS açısından etkin bulundu. Yan etkiler tolere edilebilir ve tedavi edilebilir yan etkilerdi. Çalışmamızda hipotiroidi gelişen hastalarda 32 hafta, gelişmeyelerde ise 16 haftalık bir PFS elde edildi. Bu açıdan hipotiroidi gelişim yanıt için bir prediktif parametre olabilir.

Anahtar Kelimeler

• pazopanib
• hipotiroidi
• yan etki
• sarkom

Kaynakça

1. 1. World Health Organization Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours, 5th ed, International Agency for Research on Cancer, 2020. Vol 3.
2. 2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72:7.
3. 3. Zagars GK, Ballo MT, Pisters PW et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97:2530.
4. 4. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91:1914.
5. 5. Rubin BP, Fletcher CD, Inwards C SJ et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006; 130:1616.
6. 6. Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350.
7. 7. Deroose JP, Eggermont AM, van Geel AN et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011;29(30):4036–4044.
8. 8. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647–1654.

9. 9. Mouridsen HT, Bastholt L, Somers R et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987;23(10):1477–83
10. 10. Gril B, Palmieri D, Qian Y et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and antiangiogenic effects of pazopanib in xenograft tumor models. PLoS One. 2011;6:e25625.
11. 11. Kumar R, Knock V, Rudolph S et al. Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–2021.
12. 12. Van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886.
13. 13. Coens C, van der Graaf WT, Blay JY et al. Health-related quality- of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer 2015; 121:2933.
14. 14. Ezponda A, De La Hubera IG, Calvo M, Idoate MA, Vivas I. Chronic active hepatitis induced by pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: a case report. Oncol Lett 2018; 16: 4043–8.
15. 15. Karaağaç M, Sezgin Y, Eryılmaz MK, Araz M, Kaplan MA, Artaç M. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: a Retrospective Cross-Sectional Study of a Turkish cohort. J Oncol Pharm Pract. 2020;26(7):1657–1666.
16. 16. Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92:3531
17. 17. Torino F, Corsello SM, Longo R, Barnabei A, Gasiparini G Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6:219.
18. 18. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36: 491–503.